• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form NT 20-F filed by Moolec Science SA

    10/31/25 8:05:56 PM ET
    $MLEC
    Blank Checks
    Finance
    Get the next $MLEC alert in real time by email
    NT 20-F 1 ea0263368-nt20f_moolec.htm NOTIFICATION OF LATE FILING

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

      FORM 12b-25 SEC FILE NUMBER

    001-41586

     

    CUSIP NUMBER

      NOTIFICATION OF LATE FILING L64875104

     

    ☐ Form 10-K ☒ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form 10-D ☐ Form N-SAR ☐ Form N-CSR

     

    For Period Ended: June 30, 2025

     

    ☐Transition Report on Form 10-K
    ☐Transition Report on Form 20-F
    ☐Transition Report on Form 11-K
    ☐Transition Report on Form 10-Q
    ☐Transition Report on Form N-SAR

     

    For the Trans ition Period Ended:________________________

     

    Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.

     

    If the notification relates to a portion of the filing checked above, identify the item(s) to which the notification relates: _______________________________________________________________________

     

    PART I - REGISTRANT INFORMATION

     

    Moolec Science SA
    Full name of registrant
     
     
    Former name if applicable:
     
    89 Nexus Way, Camana Bay
    Address of principal executive office
     
    Grand Cayman KY1-9009, Cayman Islands
    City, state and zip code

     

    PART II - RULES 12b-25 (b) AND (c)

     

    If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25 (b), the following should be completed. (Check box if appropriate.)

     

    ☒(a) The reasons described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;

     

     (b) The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-SAR or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and

     

     (c) The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

     

     

     

     

    PART III - NARRATIVE

     

    State below in reasonable detail why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-SAR, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period.

     

    Moolec Science SA (the “Company”) is unable to file its Annual Report on Form 20-F in a timely manner due to complexities that arose immediately after the closing of the business combination, consummated in June 2025. Subsequent to the consummation of the business combination, the Company lost the de facto control of Bioceres Crop Solutions Corp. Around the same time, Bioceres S.A. initiated a restructuring of its financial debt totaling $36.4 million, while Bioceres LLC defaulted on debt obligations of approximately $60 million. These developments required substantial time and effort from the new management to assess and address uncertainties affecting the Company’s consolidated financial position. In addition, as part of a broader restructuring initiative undertaken by the new Board of Directors and executive management, significant attention and resources were devoted to ensuring the accuracy, consistency, and completeness of the Company’s financial records and public disclosures. The transition process also required management to resolve outstanding obligations incurred by the former administration toward various suppliers and service providers. Collectively, these inherited challenges have resulted in unavoidable delays in the application of purchase accounting principles related to the business combination, rendering timely filing impracticable despite the Company’s diligent efforts.

     

    Moreover, on October 2, 2025, the Company received a notice of alleged breach from INVIM Corporativo S.L., a private limited company incorporated under the laws of Spain (“INVIM”), regarding the alleged failure to pay the Assignment Price equal to $13 million related to a certain Assignment and Assumption Agreement, dated May 27, 2025 (the “Agreement”). The Agreement in turn references related instruments, including a Note Purchase Agreement and a Binding Contribution Memorandum of Understanding, both dated October 15, 2023. In response, the Company rejected INVIM’s assertion that any payment is due or owing because, among other reasons, under the plain terms of the Agreement and related transaction instruments, INVIM failed to ever satisfy certain conditions precedent, including failing to validly transfer relevant securities or execute a required services agreement, as disclosed in the Form 6-K filed with the SEC on October 21, 2025. This matter, combined with the inherited financial and debt-related findings identified following the closing of business combination (as disclosed in the Form 6-K filed with the SEC on August 8, 2025), and the subsequent restructuring process, has temporarily diverted management's focus and resources.

     

    The Company is diligently finalizing its 2025 Form 20-F and expects to file as soon as practicable after completing the necessary assessments over accounting procedures. However, the Company does not currently anticipate being able to do so within the fifteen-day extension period provided under Rule 12b-25 of the Securities Exchange Act of 1934, as amended. As a result, the Company expects to disclose a material weakness with regard to having sufficient resources to complete the application of purchase accounting principles associated with the business combination on a timely basis. There can be no assurances that there will not be other material weaknesses until the Company completes all of its internal controls over financial reporting and financial statement preparation.

     

    PART IV - OTHER INFORMATION

     

    (1)Name and telephone number of person to contact in regard to this notification.

     

    Valeria Falottico   (54911)   6486 0236
    (Name)   (Area Code)   (Telephone Number)

     

    (2)Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s). ☒ Yes ☐ No

     

    (3)Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof? ☒ Yes ☐ No

     

    The Company included a disclosure of substantial doubt regarding its ability to continue as a going concern in its updated audited consolidated financial statements as of June 30, 2024 and 2023 and for the years ended June 30, 2024, 2023 and 2022, which were included in its current report on Form 6-K (File No. 001-41586), filed with the SEC on August 11, 2025. The Company currently expects that its consolidated financial statements for the fiscal year ended June 30, 2025 will likewise be prepared on a going concern basis and will include a similar reference to substantial doubt about the Company's ability to continue as a going concern.

     

     

    1

     

     

    Moolec Science SA

    (Name of Registrant as Specified in Charter)

     

    has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.

     

    Date: October 31, 2025 By: /s/ Alejandro Antalich
      Name:  Alejandro Antalich
      Title: Chief Executive Officer

     

     

    2

     

     

    Get the next $MLEC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MLEC

    DatePrice TargetRatingAnalyst
    9/27/2023$5.00Buy
    ROTH MKM
    More analyst ratings

    $MLEC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Moolec Has Received USDA Approval for the First Genetically Modified Pea in History

    LUXEMBOURG / ACCESSWIRE / October 16, 2024 / Moolec Science SA (NASDAQ:MLEC) ("the Company"), a leader in Molecular Farming technology, announced today that the U.S. Department of Agriculture's ("USDA") Animal and Plant Health Inspection Service ("APHIS") has completed its Regulatory Status Review ("RSR") for the Company's genetically engineered ("GE") peas which produce iron through bovine meat proteins. This is the third regulatory clearance from USDA-APHIS achieved by Moolec in an 18-month window, alongside its genetically engineered safflower and soybean for GLASO™ and Piggy Sooy™ products, respectively. Access the official USDA-APHIS publication here. "With USDA approval for our GE pe

    10/16/24 6:00:00 AM ET
    $MLEC
    Blank Checks
    Finance

    Moolec Science Presents Fiscal Year 2024 Annual Business Update

    LUXEMBOURG / ACCESSWIRE / October 2, 2024 / Moolec Science SA (NASDAQ:MLEC) ("The Company"; "Moolec"), a science-based food ingredient company focused on producing animal proteins and nutritional oils in plants, today reported its Business Update for the fourth quarter of Fiscal Year 2024 ended June 30, 2024. Moolec Science Logo The main highlights of Moolec's fourth quarter are as follows:GLASO™: The Company announced an offtake agreement with a major global CPG food and pet food company and an R&D collaboration agreement with Bunge. Also, Moolec made significant advancements in both upstream and downstream processes.Piggy Sooy™: Field trials in three different US locations continue on sch

    10/2/24 6:00:00 AM ET
    $MLEC
    Blank Checks
    Finance

    Moolec Science to Host Fourth Quarter Fiscal Year 2024 Business Update Conference Call

    LUXEMBOURG / ACCESSWIRE / September 25, 2024 / Moolec Science SA (NASDAQ:MLEC)("The Company"; "Moolec"), a science-based food ingredient company focused on producing animal proteins and nutritional oils in plants, announced today that it will release its Business Update for the Fourth Quarter and Full Fiscal Year 2024 on Wednesday, October 2, 2024, before the market opens.Moolec Sciences Logo Moolec's Chief Executive Officer Gastón Paladini, Chief Financial Officer José López Lecube, and Chief Science Officer Amit Dhingra, will host a live Conference Call, followed by a question-and-answer session, on Wednesday, October 2, 2024 at 08:30am ET.The Conference Call will be accompanied by a pr

    9/25/24 6:00:00 AM ET
    $MLEC
    Blank Checks
    Finance

    $MLEC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    ROTH MKM initiated coverage on Moolec Science with a new price target

    ROTH MKM initiated coverage of Moolec Science with a rating of Buy and set a new price target of $5.00

    9/27/23 7:44:02 AM ET
    $MLEC
    Blank Checks
    Finance

    $MLEC
    SEC Filings

    View All

    SEC Form 6-K filed by Moolec Science SA

    6-K - Moolec Science SA (0001937737) (Filer)

    12/12/25 4:43:04 PM ET
    $MLEC
    Blank Checks
    Finance

    SEC Form 6-K filed by Moolec Science SA

    6-K - Moolec Science SA (0001937737) (Filer)

    11/28/25 2:14:57 PM ET
    $MLEC
    Blank Checks
    Finance

    SEC Form 6-K filed by Moolec Science SA

    6-K - Moolec Science SA (0001937737) (Filer)

    11/20/25 4:15:04 PM ET
    $MLEC
    Blank Checks
    Finance

    $MLEC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D filed by Moolec Science SA

    SC 13D - Moolec Science SA (0001937737) (Subject)

    4/17/24 5:14:28 PM ET
    $MLEC
    Blank Checks
    Finance

    SEC Form SC 13D/A filed by Moolec Science SA (Amendment)

    SC 13D/A - Moolec Science SA (0001937737) (Subject)

    4/10/24 9:39:03 PM ET
    $MLEC
    Blank Checks
    Finance

    $MLEC
    Financials

    Live finance-specific insights

    View All

    Moolec Science Presents Fiscal Year 2024 Annual Business Update

    LUXEMBOURG / ACCESSWIRE / October 2, 2024 / Moolec Science SA (NASDAQ:MLEC) ("The Company"; "Moolec"), a science-based food ingredient company focused on producing animal proteins and nutritional oils in plants, today reported its Business Update for the fourth quarter of Fiscal Year 2024 ended June 30, 2024. Moolec Science Logo The main highlights of Moolec's fourth quarter are as follows:GLASO™: The Company announced an offtake agreement with a major global CPG food and pet food company and an R&D collaboration agreement with Bunge. Also, Moolec made significant advancements in both upstream and downstream processes.Piggy Sooy™: Field trials in three different US locations continue on sch

    10/2/24 6:00:00 AM ET
    $MLEC
    Blank Checks
    Finance

    Moolec Science to Host Fourth Quarter Fiscal Year 2024 Business Update Conference Call

    LUXEMBOURG / ACCESSWIRE / September 25, 2024 / Moolec Science SA (NASDAQ:MLEC)("The Company"; "Moolec"), a science-based food ingredient company focused on producing animal proteins and nutritional oils in plants, announced today that it will release its Business Update for the Fourth Quarter and Full Fiscal Year 2024 on Wednesday, October 2, 2024, before the market opens.Moolec Sciences Logo Moolec's Chief Executive Officer Gastón Paladini, Chief Financial Officer José López Lecube, and Chief Science Officer Amit Dhingra, will host a live Conference Call, followed by a question-and-answer session, on Wednesday, October 2, 2024 at 08:30am ET.The Conference Call will be accompanied by a pr

    9/25/24 6:00:00 AM ET
    $MLEC
    Blank Checks
    Finance

    Moolec Science to Host Third Quarter Fiscal Year 2024 Business Update Conference Call

    LUXEMBOURG / ACCESSWIRE / May 23, 2024 / Moolec Science SA (NASDAQ:MLEC)("Company"; "Moolec"), a science-based food ingredient company focused on producing animal proteins in plants through Molecular Farming, announced today that it will release its Business Update for the Third Quarter Fiscal Year 2024 on Thursday, May 30, 2024, before the market opens. Moolec Logo Moolec Science Logo Moolec's Chief Executive Officer Gastón Paladini, Chief Financial Officer José López Lecube, and Chief Science Officer Amit Dhingra, will host a live Conference Call, followed by a question-and-answer session, on Thursday, May 30, 2024, at 08:30 a.m. ET.The Conference Call will be accompanied by a presentation

    5/23/24 7:00:00 AM ET
    $MLEC
    Blank Checks
    Finance